Ustekinumab remission in pediatric UC by prior biologic

What is known

• The one pediatric anti-TNF–refractory UC study reports that 9/10 children achieved steroid-free clinical remission on ustekinumab over a median 56-week follow-up. ¹

What is unknown / caveats

• No excerpt addresses whether remission duration on ustekinumab differs by prior vedolizumab exposure versus anti-TNF only in pediatric UC.
• That single pediatric study does not stratify or compare outcomes by prior vedolizumab exposure.

References

1. Rehman R, Riaz MS, Esharif D, Has P, Herzlinger M, Shapiro J, Subedi S. Ustekinumab for anti-tumor necrosis factor refractory pediatric ulcerative colitis: a promising approach towards endoscopic healing. Intest Res. 2024. PMID: 38311714.

For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.

Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct.